According to a recently published report by Research Nester on “Hormone Replacement Therapy Market: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the hormone replacement therapy in terms of market segmentation by product, by route of administration, by type of disease and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The global hormone replacement therapy market is segmented by product into estrogen replacement, human growth hormone replacement, thyroid replacement and others; by route of administration into oral, parental, transdermal and others; by type of disease into menopause, hypothyroidism, male hypothyroidism, growth hormone deficiency, cancer & others. The global hormone replacement therapy market is anticipated to record a CAGR of 7.65% over the forecast period i.e. 2019-2027.
Increasing Hormonal Imbalance Disorder
Hormone Replacement Therapy (HRT) has been utilized and initiated in treating various disorders one of which is during the early stages of menopause. In older women and women more than 10 years past menopause, the risk-benefit balance of HRT is less favorable, particularly with regard to cardiovascular risk and cognitive impairment. Such factors are expected to drive the market over the forecast period.
Introduction of Transdermal Drug Delivery System
Transdermal sprays is intended as metered-dose spray (MDTS) to deliver certain amount of formulation through the skin. Following a once daily application, a sustained and enhanced penetration of drug across the skin can be achieved from the stratum corneum reservoir. The physicochemical features of non-volatile constituents are selected to improve infiltration. Thus, this type of transfer system produces an invisible spot of drug and enhancer in the stratum corneum from which the drug can be gradually immersed into the systemic rotation. This can offer transfer of drug over two to four days subsequent a single application and constant steady-state serum levels.
Irregular bleeding in the first few months of taking any form of HRT is a major concern. The low awareness about the benefits of HRT among people is further expected to hamper the market growth over the forecast period. However, other side effects that can occur such as breast tenderness and enlargement, leg cramps, bloating, headache, pre- and menstrual symptoms may limit the market in near future.
The market in North America is expected to display a strong growth on the back of increasing number of hormonal imbalance disorder along with rising number of menopausal women. Further, the Europe market is anticipated to induce a growth owing to advancement in technology such as gel-based formulation and transdermal drug delivery system.
This report also provides the existing competitive scenario of some of the key players of the hormone replacement therapy market which includes company profiling of Novo Nordisk, Novartis, Merck Serono, Bayer Healthcare, Eli Lilly Mylan Laboratories, Roche, Genentech, Orion Pharma AB, Allergen Plc and other prominent players. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the hormone replacement therapy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.